Real-world outcomes among patients with metastatic colorectal cancer treated first line with a bevacizumab biosimilar (bevacizumab-awwb).

ABSTRACT:

Background

Bevacizumab-awwb (MVASI^®) was the first U.S. Food and Drug Administration-approved biosimilar to Avastin^® (reference product [RP]) for the treatment of several different types of cancers, including metastatic colorectal cancer (mCRC), an indication approved based on extrapolation.

Objectives

Evaluate treatment outcomes in mCRC patients who received first-line (1L) bevacizumab-awwb at treatment initiation or as continuing bevacizumab therapy (switched from RP).

Design

A retrospective chart review study.

Methods

Adult patients who had a confirmed diagnosis of mCRC (initial presentation of CRC on or after 01 January 2018) and initiated 1L bevacizumab-awwb between 19 July 2019 and 30 April 2020 were identified from the ConcertAI Onc

SUBMITTER: Jin R 

PROVIDER: S-EPMC10288425 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature